Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.77 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.77 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018017 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL399278 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL30734435 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL27075590 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL19464266 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL7447363 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL31018036 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877853 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877854 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877856 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| EP-3442516-B1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIV CANBERRA (AU) | 2025-11-12 | — | — | EP | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| EP-4541372-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | Matsumoto, Shinichi (JP) | 2025-04-23 | — | — | EP | claimed |
| CN-119384295-A | Medication of obsessive-compulsive disorder targeting dopamine D1 signaling of striatal bodies | 松本真一 | 2025-01-28 | — | — | CN | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | claimed |
| US-20220370471-A1 | COMPOSITION AND METHOD FOR TREATMENT OF HIPPOCAMPAL SYNAPSE DYSFUNCTION AND COGNITIVE DEFICITS IN ALZHEIMER'S DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-24 | — | — | US | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| US-20220047529-A1 | METHODS OF INHIBITION | UNIVERSITY OF CANBERRA (AU) | 2022-02-17 | — | — | US | claimed |
| CN-112770734-A | Suppression method | 堪培拉大学 | 2021-05-07 | — | — | CN | claimed |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2021-03-18 | — | — | US | claimed |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | UNIVERSITY OF CANBERRA (AU) | 2020-12-29 | — | — | US | claimed |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | UNIVERSITY OF CANBERRA (AU) | 2019-05-23 | — | — | US | claimed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4883/4885KDM4E 2919/4885TP53 2661/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885KDM4E 3556/4885TP53 4088/4885 |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A13 | DRD1 11/4885KDM4E 3950/4885TP53 3169/4885 |
| US-20220047529-A1 | METHODS OF INHIBITION | SLC6A3, DBH, SNCA | DRD1 4/4885KDM4E 1444/4885TP53 4537/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885KDM4E 3556/4885TP53 4088/4885 |
| US-10874629-B2 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | COMT, LRRK2, PARK7 | DRD1 341/4885KDM4E 2126/4885TP53 4589/4885 |
| US-20190151270-A1 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | COMT, LRRK2, PARK7 | DRD1 341/4885KDM4E 2126/4885TP53 4589/4885 |
| US-20210077443-A1 | OPHTHALMIC COMPOSITIONS INCLUDING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | TTPA, TST, TXN2 | DRD1 1876/4885KDM4E 1593/4885TP53 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.